Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors

Journal of Neuro-Oncology

Volumn 86, Issue 2, 2008, Pages 175-181

  Wagner, Sabine ^a,b   Peters, Ove ^a,b   Fels, Christin ^a,b   Janssen, Gisela ^c   Liebeskind, Anne Kathrin ^d   Sauerbrey, Axel ^e   Suttorp, Meinolf ^f   Hau, Peter ^b   Wolff, Johannes E A ^b,g  

^a Krankenhaus der Barmherzigen Bruder   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d HELIOS KLINIKUM BERLIN BUCH   (Germany)

^e HELIOS KLINIKUM ERFURT   (Germany)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Brain tumors; Children; Liposomal doxorubicin; Oral topotecan

Indexed keywords

DOXORUBICIN; MACROGOL; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; TOPOTECAN;

ADOLESCENT; ARTICLE; BRAIN CANCER; CANCER GRADING; CANCER RELAPSE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HAND FOOT SYNDROME; HEART DISEASE; HEART LEFT VENTRICLE FUNCTION; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INDIVIDUALIZATION; INFECTION; LEUKOPENIA; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NAUSEA; PATIENT CARE; PHARYNGITIS; RECOMMENDED DRUG DOSE; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA; CHILD; CHILD, PRESCHOOL; CHOROID PLEXUS NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; GLIOBLASTOMA; HEMATOLOGIC DISEASES; HUMANS; NEOPLASM RECURRENCE, LOCAL; POLYETHYLENE GLYCOLS; RECURRENCE; RETROSPECTIVE STUDIES; STOMATITIS; TOPOTECAN; TREATMENT OUTCOME;

EID: 37249006756     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9444-x     Document Type: Article

References (33)

1. Parimoo D, Garcia A, Roman L et al (2000) Phase I trial of liposomal doxorubicin-Doxil(d) and topotecan (t) in advanced pelvic malignancies. Proc Am Soc Clin Oncol 19:1616
2. Pautier P, Germann N, Faivre S et al (2000) Phase I study of Caelyx (KLX-Stealth stabilized liposomal doxorubcin-Doxil) in combination with topotecan. Proc Am Soc Clin Oncol 19:910
3. Hamilton A, Hochster H, Rosenthal M et al (2000) Continuous infusion topotecan (TP-Cl) with doxil (Dx): A phase I study of dual topoisomerase inhibition. Proc Am Soc Clin Oncol 19:777
4. Voest EE, Verhaar MJ (2001) A phase II study of the combination Doxil and topotecan in platinum resistant ovarian cancer. Proc Am Soc Clin Oncol 20:2479
5. Geertsen PF, Stroyer I, Herrstedt J et al (2001) Phase I study of topotecan (T) and pegylated liposomal doxorubicin (Caelyx) in patients (pts) with progressive ovarian cancer within 12 months after first-line platinum-paclitaxel containing chemotherapy. Proc Am Soc Clin Oncol 20:2479
6. Blum RH, Carter SK (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80:249-259
7. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741
8. De Graff WG, Myers LS Jr, Mitchell JB et al (2003) Protection against Adriamycin (R) cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid. Int J Oncol 23:159-163
9. Burden DA, Osheroff N (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1400:139-154
10. Bottero V, Busuttil V, Loubat A et al (2001) Activation of nuclear factor κB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: A brake to apoptosis in HeLa human carcinoma cells. Cancer Res 61:7785-7791
11. Wolff JE, Trilling T, Molenkamp G et al (1999) Chemosensitivity of glioma cells in vitro: A meta analysis. J Cancer Res Clin Oncol 125:481-486
12. Stan AC, Casares S, Radu D et al (1999) Doxorubicin-induced cell death in highly invasive human gliomas. Anticancer Res 19:941-950
13. Valdivieso M, Burgess MA, Ewer MS et al (1984) Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: A prospective, randomized study. J Clin Oncol 2:207-214
14. Paridaens R (1998) Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: A literature survey. Semin Oncol 25:3-6
15. Siegal T, Horowitz A, Gabizon A (1995) Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: Biodistribution and therapeutic efficacy. J Neurosurg 83:1029-1037
16. Vaage J, Barbera-Guillem E, Abra R et al (1994) Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73:1478-1784
17. Gabizon A, Martin F (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54:15-21
18. Allen TM (1998) Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 56:747-756
19. Wagner S, Erdlenbruch B, Langler A et al (2004) Oral topotecan in children with recurrent or progressive high-grade glioma: A Phase I/II study by the German Society for pediatric oncology and hematology. Cancer 100:1750-1757
20. MacDonald D, Cairncross G, Stewart D et al (1996) National Clinical Institute of Canada Clinical Trials Group. Phase II study of topotecan in patients with recurrent malignant glioma. Ann Oncol 7:205-207
21. Blaney SM, Phillips PC, Packer RJ et al (1996) Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 78:527-531
22. Friedman HS, Kerby T, Fields S et al (1999) Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Cancer 85:1160-1316
23. McCabe FL, Johnson RK (1994) Comparative activity of oral and parenteral topotecan in murine tumor models: Efficacy of oral topotecan. Cancer Invest 12:308-313
24. De Cesare M, Zunino F, Pace S et al (2000) Efficacy and toxicity profile of oral topotecan in a panel of human tumor xenografts. Eur J Cancer 36:1558-1564
25. Pratesi G, De Cesare M, Zunino F (2000) Improvement of therapeutic index of low-dose topotecan delivered per os. Ann NY Acad Sci 922:330-333
26. Saylors RL 3rd, Stine KC, Sullivan J et al (2001) Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol 19:3463-3469
27. Wolff JE, Molenkamp G, Westphal S, Pietsch T, Gnekow A, Kortmann RD, Kuehl J (2000) Oral trofosfamide and etoposide in pediatric patients with glioblastoma multiforme. Cancer 89:2131-2137
28. Fabel K, Dietrich J, Hau P et al (2001) Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92:1936-1942
29. Hau P, Fabel K, Baumgart U et al (2004) Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100:1199-1207
30. Olson F, Mayhew E, Maslow D, Rutsum Y, Szoka F (1982) Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer Clin Oncol 18:167-176
31. Harris L, Batist G, Belt R et al (2002) TLC D-99 Study Group. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94:25-36
32. Lyass O, Uziely B, Ben-Yosef R et al (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89:1037-1047
33. Marina NM, Cochrane D, Harney E et al (2002) Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: A pediatric oncology group study. Clin Cancer Res 8:413-418